U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019324) titled 'BDNF Levels in Cancer Patients Receiving Chemotherapy' on June 05.
Brief Summary: Cognitive impairment following chemotherapy is defined as chemotherapy-induced cognitive impairment (CCIID). CCIID, which significantly reduces the quality of life of cancer patients receiving chemotherapy, develops as a result of neurotoxicity. It is stated that 75% of patients receiving chemotherapy have cognitive changes. In addition, 35% of patients complain of various cognitive impairments (hearing, perception, decision-making, etc.) for a few months after chemotherapy ends. This situation makes life conditions very difficult for patients who are ...